SYBX

Synlogic Inc. (SYBX) | Rumor.io

Synlogic

SYBX

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)100%

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-1M

Social

What share of all stock conversation is about SYBX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% new	0% 0

Jan 20

Synlogic, Inc. ($SYBX) is facing delisting from NASDAQ on January 21, 2026, after withdrawing its appeal.
The company will move to OTC markets and is expected to experience high volatility, with a potential major volume spike.
The delisting and subsequent transition to OTC markets may create a potential entry point for disciplined investors.

Generated by AI

Sentiment

Of the messages about SYBX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	82.5% -17.5
Bearish	—	—	—	17.5% new

Bullish· Sep 20

$SYBX has executed well in the clinic, hitting timelines and saving the company with the Gingko deal, and now has a drug in development.
The company's Phase II data in PKU was positive, demonstrating a reduction in plasma phenylalanine levels in patients, which is a major milestone in the development of living, engineered probiotics medicines.
Piper Sandler has maintained an Overweight rating on $SYBX and raised its price target to $7-$9, indicating strong potential for future growth.

Bearish· Feb 9

Synlogic, Inc. ($SYBX) is ceasing operations and laying off over 90% of its workforce due to a failed trial and discontinued study.
Analysts are downgrading Synlogic's stock, with HC Wainwright downgrading to Sell from Buy and SVB Leerink and Chardan Capital also downgrading their ratings.
Synlogic's stock has plummeted, with prices down 51-56% in pre-market trading, and some analysts calling the company's situation a "sudden and stunning implosion".

Generated by AI

Topics

Of the messages about SYBX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	1.82%
Announcements	—	—	—	92.73%
Controversies	—	—	—	0%
Earnings	—	—	—	1.82%
Macro	—	—	—	0%
Technical Analysis	—	—	—	3.64%

Feb 8

Synlogic, Inc. ($SYBX) has discontinued its Synpheny-3 study and will cease operations, reducing its workforce by over 90%.
The decision to end the study was based on an internal review indicating it was unlikely to meet its primary endpoint, and the company will now evaluate strategic options to enhance shareholder value.
Synlogic's management and board will conduct a review of strategic options, which may include acquisitions, mergers, or sales of assets, with a cash balance of $47.7M as of December 31, 2023.

Generated by AI

Community

Of the messages about SYBX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	0%	14.8%
Newcomers	—	—	100%	85.2%

Regulars· Feb 9

Synlogic, Inc. (SYBX) has pulled the plug on its lead program for a treatment candidate for phenylketonuria, citing initial data that suggests the trial is unlikely to meet its primary endpoint.
The company has initiated a review of strategic alternatives, and its stock is down nearly 50% today.
SVB Leerink, Chardan Capital, and HC Wainwright have all downgraded their ratings on SYBX, with SVB Leerink moving from Outperform to Market Perform, Chardan Capital from Buy to Neutral, and HC Wainwright from Buy to Sell.

Newcomers· Jun 8

Synlogic, Inc. (SYBX) will hold its 2023 Annual General Meeting of Stockholders on June 15, 2023, in a virtual meeting format only.
Stockholders can access the meeting online and vote their shares via the company's website.
The meeting will take place on Thursday, June 15, 2023 at 8:00 a.m. EST.

Generated by AI

Also Discussed

Investors talking about SYBX also mention

#	Name	Attention
1	AFMD - Affimed N.V.	——
2	TCON - TRACON Pharmaceuticals, Inc.	——
3	Ginkgo Bioworks Holdings, Inc. Class A Common StockDNA	0.02%new
4	TLIS - Talis Biomedical Corporation	——
5	Evelo Biosciences Inc.EVLO	0%0
6	JNCE - Jounce Therapeutics, Inc.	——
7	BLCM - Bellicum Pharmaceuticals, Inc.	——
8	ADVM - Adverum Biotechnologies, Inc.	——
9	Cyclerion Therapeutics IncCYCN	0%new
10	YTEN - Yield10 Bioscience, Inc.	——

Synlogic Inc.

Healthcare
Biotechnology

Synlogic Inc., a clinical-stage biotechnology company, is at the forefront of developing synthetic biotic medicines. These innovative therapeutics are designed using synthetic biology to address significant unmet medical needs. By engineering beneficial probiotic bacteria to perform specific metabolic functions in the human body, Synlogic aims to treat complex diseases where traditional pharmaceuticals may fall short. The company's unique approach has implications across various areas, such as genetic and metabolic disorders, immunological conditions, and even oncology. Synlogic Inc. collaborates with academic institutions and industry leaders to advance its research and development efforts. As a key player in the biotechnology sector, its work highlights the potential of synthetic biology in revolutionizing patient care and broadening treatment options for challenging medical conditions.

Website

Location

PO Box 30

Winchester, MA, 01890

United States

Social

What share of all stock conversation is about SYBX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% new	0% 0

Jan 20

Synlogic, Inc. ($SYBX) is facing delisting from NASDAQ on January 21, 2026, after withdrawing its appeal.
The company will move to OTC markets and is expected to experience high volatility, with a potential major volume spike.
The delisting and subsequent transition to OTC markets may create a potential entry point for disciplined investors.

Generated by AI

Sentiment

Of the messages about SYBX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	82.5% -17.5
Bearish	—	—	—	17.5% new

Bullish· Sep 20

$SYBX has executed well in the clinic, hitting timelines and saving the company with the Gingko deal, and now has a drug in development.
The company's Phase II data in PKU was positive, demonstrating a reduction in plasma phenylalanine levels in patients, which is a major milestone in the development of living, engineered probiotics medicines.
Piper Sandler has maintained an Overweight rating on $SYBX and raised its price target to $7-$9, indicating strong potential for future growth.

Bearish· Feb 9

Synlogic, Inc. ($SYBX) is ceasing operations and laying off over 90% of its workforce due to a failed trial and discontinued study.
Analysts are downgrading Synlogic's stock, with HC Wainwright downgrading to Sell from Buy and SVB Leerink and Chardan Capital also downgrading their ratings.
Synlogic's stock has plummeted, with prices down 51-56% in pre-market trading, and some analysts calling the company's situation a "sudden and stunning implosion".

Generated by AI

Topics

Of the messages about SYBX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	1.82%
Announcements	—	—	—	92.73%
Controversies	—	—	—	0%
Earnings	—	—	—	1.82%
Macro	—	—	—	0%
Technical Analysis	—	—	—	3.64%

Feb 8

Synlogic, Inc. ($SYBX) has discontinued its Synpheny-3 study and will cease operations, reducing its workforce by over 90%.
The decision to end the study was based on an internal review indicating it was unlikely to meet its primary endpoint, and the company will now evaluate strategic options to enhance shareholder value.
Synlogic's management and board will conduct a review of strategic options, which may include acquisitions, mergers, or sales of assets, with a cash balance of $47.7M as of December 31, 2023.

Generated by AI

Community

Of the messages about SYBX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	0%	14.8%
Newcomers	—	—	100%	85.2%

Regulars· Feb 9

Synlogic, Inc. (SYBX) has pulled the plug on its lead program for a treatment candidate for phenylketonuria, citing initial data that suggests the trial is unlikely to meet its primary endpoint.
The company has initiated a review of strategic alternatives, and its stock is down nearly 50% today.
SVB Leerink, Chardan Capital, and HC Wainwright have all downgraded their ratings on SYBX, with SVB Leerink moving from Outperform to Market Perform, Chardan Capital from Buy to Neutral, and HC Wainwright from Buy to Sell.

Newcomers· Jun 8

Synlogic, Inc. (SYBX) will hold its 2023 Annual General Meeting of Stockholders on June 15, 2023, in a virtual meeting format only.
Stockholders can access the meeting online and vote their shares via the company's website.
The meeting will take place on Thursday, June 15, 2023 at 8:00 a.m. EST.

Generated by AI

Synlogic

Social

Jan 20

Sentiment

Bullish· Sep 20

Bearish· Feb 9

Topics

Feb 8

Community

Regulars· Feb 9

Newcomers· Jun 8

Also Discussed

Synlogic Inc.

Company Information

Location

Also Discussed

Social

Jan 20

Sentiment

Bullish· Sep 20

Bearish· Feb 9

Topics

Feb 8

Community

Regulars· Feb 9

Newcomers· Jun 8